Veradermics (MANE) Profit After Tax (2025 - 2026)

Veradermics (MANE) posted Profit After Tax of -$584000.0 for Q1 2026, up 96.0% on a QoQ basis from -$14.6 million in Q1 2025, and up 96.0% year-over-year from -$297966.7 in Q1 2025.

Veradermics (MANE) Profit After Tax (2025 - 2026) Analysis & Trends

Veradermics' Profit After Tax history runs 2 years deep, the most recent figure standing at -$584000.0 for Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -36.84 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 227.36 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -65.60 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -26.94 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 362.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - -453.82 Mn
10 Veradermics 2.63 Bn 2.63 Bn - -584,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -584,000.00
Mar 31, 2025 -14.58 Mn